Villanova Investment Management Co LLC Sells 37,445 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Villanova Investment Management Co LLC trimmed its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 65.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 19,587 shares of the specialty pharmaceutical company’s stock after selling 37,445 shares during the period. Supernus Pharmaceuticals accounts for 1.8% of Villanova Investment Management Co LLC’s investment portfolio, making the stock its 22nd largest holding. Villanova Investment Management Co LLC’s holdings in Supernus Pharmaceuticals were worth $641,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of SUPN. Acadian Asset Management LLC raised its position in shares of Supernus Pharmaceuticals by 309.6% in the first quarter. Acadian Asset Management LLC now owns 9,174 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 6,934 shares during the period. Intech Investment Management LLC boosted its position in shares of Supernus Pharmaceuticals by 26.4% during the 1st quarter. Intech Investment Management LLC now owns 35,828 shares of the specialty pharmaceutical company’s stock worth $1,173,000 after acquiring an additional 7,476 shares in the last quarter. Jane Street Group LLC bought a new position in Supernus Pharmaceuticals in the first quarter valued at about $3,641,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Supernus Pharmaceuticals by 7.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 107,789 shares of the specialty pharmaceutical company’s stock valued at $3,530,000 after purchasing an additional 7,769 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in shares of Supernus Pharmaceuticals by 16.0% during the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 6,619 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 0.4%

Shares of SUPN opened at $46.21 on Thursday. The firm’s fifty day simple moving average is $38.86 and its two-hundred day simple moving average is $34.40. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $46.78. The stock has a market capitalization of $2.59 billion, a P/E ratio of 40.18 and a beta of 0.79.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 6,322 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $46.29, for a total transaction of $292,645.38. Following the transaction, the chief executive officer directly owned 1,111,983 shares in the company, valued at approximately $51,473,693.07. This represents a 0.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frederick M. Hudson sold 7,457 shares of the firm’s stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the sale, the director directly owned 46,307 shares of the company’s stock, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 241,506 shares of company stock worth $10,466,794 over the last quarter. 8.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on SUPN. Wall Street Zen upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Piper Sandler raised their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a “neutral” rating in a research note on Friday, August 29th. Finally, Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.